Latest news and press releases about Nyxoah S.A. (NYXH): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Nyxoah SA, a medical technology company, develops and commercializes solutions to treat obstructive sleep apnea (OSA). The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, minimally invasive, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea. Nyxoah SA was incorporated in 2009 and is headquartered in Mont-Saint-Guibert, Belgium.
Price
| Price | $1.55 |
| Market Cap | $155M |
| Exchange | NASDAQ |
| Country | BE |
Valuation Ratios
| Price / Book | 0.91 |
| EV / EBITDA | -1.59 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -179.71% |
| Return on Invested Capital | -59.89% |
| Return on Assets | -58.46% |
| Gross Margin | 51.31% |
| Operating Margin | -383.05% |
| Net Margin | -434.72% |
Related companies: CATX · GNFT · IVVD · KRMD · OABI · OSUR · PRE
Explore sector: Healthcare · Medical - Specialties
More sections of NYXH: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks